{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:50Z","timestamp":1790717030139,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric acute lymphoblastic leukemia (ALL), the most common childhood malignancy, achieves &amp;gt;95% 5-year survival with risk-adapted therapies. Nonetheless, 10%\u201315% of patients experience relapse, with post-relapse survival &amp;lt;50%. Challenges remain in optimizing minimal residual disease (MRD)-guided strategies and salvage therapies in ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to identify relapse predictors and assess post-relapse outcomes among 436 pediatric ALL patients treated according to the CCCG-ALL-2015 protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 436 enrolled patients (median age: 3.9 years; 92.4% B-ALL), sixty-four patients (14.7%) relapsed, predominantly with isolated bone marrow involvement (71.9%). Independent predictors included thrombocytopenia at diagnosis (OR\u2009=\u20092.09,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.037),\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      (+) (OR\u2009=\u20093.85,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.024), and positive MRD on day 19 (OR\u2009=\u20092.09) and day 46 (OR\u2009=\u20095.73,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) of induction therapy. Post-relapse, isolated extramedullary cases showed higher OS (100% vs. 72.9%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.078) than bone marrow relapses. HSCT significantly improved OS in bone marrow relapse comparing to patients treated with chemotherapy or CAR-T alone (82.6% vs. 38.1%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Thrombocytopenia at diagnosis,\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      (+), and persistent MRD are critical relapse predictors. HSCT remains pivotal for bone marrow relapse. Incorporating platelet counts into risk stratification and optimizing MRD-guided bridging therapies may enhance outcome. Future research should prioritize thrombocytopenia mechanisms and HSCT preconditioning strategies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1710578","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:26Z","timestamp":1766040206000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pediatric acute lymphoblastic leukemia relapse and prognosis: key predictors and therapeutic implications"],"prefix":"10.3389","volume":"13","author":[{"given":"XiaoYan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LingLing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CaiYun","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaYi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenGe","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiNa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in children with standard-risk B-cell acute lymphoblastic leukemia. Results of children\u2019s oncology group trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.22.01760","article-title":"Childhood acute lymphoblastic leukemia: results of the randomized acute lymphoblastic leukemia intercontinental-Berlin-Frankfurt-munster 2009 trial","volume":"41","author":"Campbell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from children\u2019s oncology group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a children\u2019s oncology group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","article-title":"Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/cancers16050858","article-title":"Biological markers of high-risk childhood acute lymphoblastic leukemia","volume":"16","author":"He","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL consortium protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from children\u2019s oncology group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e7172","DOI":"10.1002\/cam4.7172","article-title":"Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol","volume":"13","author":"Popov","year":"2024","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2415589","DOI":"10.1080\/16078454.2024.2415589","article-title":"The significance of MRD-based strategy by dynamic assessment to guide treatment decisions in B-ALL - the enlightenment provided by demonstrating survival differences in the retrospective study","volume":"29","author":"Chen","year":"2024","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood oncology group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1200\/JCO.19.01694","article-title":"Improving stratification for children with late bone marrow B-cell acute lymphoblastic leukemia relapses with refined response classification and integration of genetics","volume":"37","author":"Eckert","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1200\/JCO.23.02238","article-title":"Genomic determinants of outcome in acute lymphoblastic leukemia","volume":"42","author":"Chang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e25548","DOI":"10.1097\/MD.0000000000025548","article-title":"Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia","volume":"100","author":"Dai","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.31557\/APJCP.2024.25.9.3229","article-title":"Peripheral blood neutrophil nadir and time to platelet recovery during induction chemotherapy: predictors of clinical outcomes and markers for optimizing induction treatment intensity in acute lymphoblastic leukemia","volume":"25","author":"Ramesh","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3324\/haematol.2011.045229","article-title":"Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome","volume":"97","author":"Zeidler","year":"2012","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1054\/bjoc.2000.1504","article-title":"Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis of a population of 1545 children treated by the French acute lymphoblastic leukaemia group (FRALLE)","volume":"83","author":"Donadieu","year":"2000","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41375-022-01540-1","article-title":"Temporal changes in incidence of relapse and outcome after relapse of childhood acute lymphoblastic leukemia over three decades; a nordic population-based cohort study","volume":"36","author":"Jensen","year":"2022","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1002\/cncr.33609","article-title":"Inaba H: testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management","volume":"127","author":"Nguyen","year":"2021","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clml.2019.10.016","article-title":"Treatment of testicular relapse of B-cell acute lymphoblastic leukemia with CD19-specific chimeric antigen receptor T cells","volume":"20","author":"Chen","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the children\u2019s oncology group phase III study AALL0433","volume":"106","author":"Lew","year":"2021","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","first-page":"923419","DOI":"10.3389\/fped.2022.923419","article-title":"Novel treatments for pediatric relapsed or refractory acute B-cell lineage lymphoblastic leukemia: precision medicine era","volume":"10","author":"Mengxuan","year":"2022","journal-title":"Front Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00277-021-04451-w","article-title":"Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R\/R B-ALL patients: a systematic review and meta-analysis","volume":"100","author":"Hu","year":"2021","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1038\/s41375-021-01236-y","article-title":"Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed\/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy","volume":"35","author":"Hu","year":"2021","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"784024","DOI":"10.3389\/fped.2021.784024","article-title":"Chimeric antigen receptor T-cell therapy in paediatric B-cell precursor acute lymphoblastic leukaemia: curative treatment option or bridge to transplant?","volume":"9","author":"Buechner","year":"2021","journal-title":"Front Pediatr"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1710578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:43:27Z","timestamp":1766040207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1710578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":28,"alternative-id":["10.3389\/fped.2025.1710578"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1710578","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"1710578"}}